Scholarlink

Background <p>Postoperative hemorrhage is one of the major complications of oral surgery. Conventional hemostatic methods, such as chair-side preparation of tranexamic acid (TXA)-soaked gauze or TXA mouthwash, often suffer from dosage variability and increased surgical time. This study aimed to develop a ready-to-use TXA gauze and to evaluate its fabrication process, hemostatic efficiency, and shelf-life stability.</p> Methods <p>Gauze samples containing TXA concentrations of 2.5% and 5% (w/v) were fabricated using a freeze-drying technique. Characterization was performed using field emission scanning electron microscope (FESEM) and fourier transform infrared spectroscopy (FTIR). The in vitro blood clotting time (BCT) and plasma recalcification time (PRT) were assessed using independent biological replicates from six healthy volunteers (<i>n</i> = 6). Biocompatibility was assessed via MTT assay on 3T3 fibroblasts. Shelf-life stability was monitored over 180 days under International Conference on Harmonisation (ICH) Zone IV conditions (30&#xa0;°C/65% RH and 4&#xa0;°C).</p> Results <p>The morphological and FTIR measurements confirmed that the gauze fibers were effectively coated with TXA. Meanwhile, the TXA impregnation did not significantly impact the gauze’s physical and biological properties. A burst release of the TXA was observed for the first 3&#xa0;min, ensuring rapid clot stabilization. In vitro coagulation tests showed that the TXA gauze significantly reduced coagulation times, enhancing the hemostatic process. Similar to 5% TXA gauze, 2.5% TXA gauze had biocompatibility and hemostatic effectiveness. This finding shows that a lower dose (2.5% w/v) achieved hemostasis, maximizing cost-effectiveness and lowering drug toxicity. Stability tests over six months at various temperatures confirmed that the TXA gauze maintained its hemostatic efficacy without significant drug degradation.</p> Conclusions <p>The prefabricated TXA gauze is a promising material, especially for patients on anticoagulant therapy, with long-term stability and practical deployment potential in clinical settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development of ready-to-use tranexamic acid gauze as a hemostatic material for oral surgery: fabrication, hemostasis, and shelf-life

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月19日

查看全文
  • Taechana Sitthikornvanich,
  • Worawut Kriangkrai,
  • Ariya Chantaramanee,
  • Rudjit Tunthasen,
  • Thanyaphat Engboonmeskul,
  • Lalitkorn Promma,
  • Teerawat Sukpaita

摘要

Background

Postoperative hemorrhage is one of the major complications of oral surgery. Conventional hemostatic methods, such as chair-side preparation of tranexamic acid (TXA)-soaked gauze or TXA mouthwash, often suffer from dosage variability and increased surgical time. This study aimed to develop a ready-to-use TXA gauze and to evaluate its fabrication process, hemostatic efficiency, and shelf-life stability.

Methods

Gauze samples containing TXA concentrations of 2.5% and 5% (w/v) were fabricated using a freeze-drying technique. Characterization was performed using field emission scanning electron microscope (FESEM) and fourier transform infrared spectroscopy (FTIR). The in vitro blood clotting time (BCT) and plasma recalcification time (PRT) were assessed using independent biological replicates from six healthy volunteers (n = 6). Biocompatibility was assessed via MTT assay on 3T3 fibroblasts. Shelf-life stability was monitored over 180 days under International Conference on Harmonisation (ICH) Zone IV conditions (30 °C/65% RH and 4 °C).

Results

The morphological and FTIR measurements confirmed that the gauze fibers were effectively coated with TXA. Meanwhile, the TXA impregnation did not significantly impact the gauze’s physical and biological properties. A burst release of the TXA was observed for the first 3 min, ensuring rapid clot stabilization. In vitro coagulation tests showed that the TXA gauze significantly reduced coagulation times, enhancing the hemostatic process. Similar to 5% TXA gauze, 2.5% TXA gauze had biocompatibility and hemostatic effectiveness. This finding shows that a lower dose (2.5% w/v) achieved hemostasis, maximizing cost-effectiveness and lowering drug toxicity. Stability tests over six months at various temperatures confirmed that the TXA gauze maintained its hemostatic efficacy without significant drug degradation.

Conclusions

The prefabricated TXA gauze is a promising material, especially for patients on anticoagulant therapy, with long-term stability and practical deployment potential in clinical settings.